Novartis drops VHB937 ALS program after Phase 2 failure on September 16, 2026 ALS Amyotrophic Lateral Sclerosis ASTRALS del-desiran lifonebart Microglia Novartis Pelacarsen Phase 2 R&D pipeline TREM2 VHB937 +
Novartis board faces investor scrutiny after M&A misfires and R&D setbacks on September 13, 2026 Artisan Partners Avidity Biosciences Clinical Trials del-desiran Giovanni Caforio investor scrutiny M&A strategy Novartis Pelacarsen +
Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers on September 11, 2026 Amgen Avidity Biosciences del-desiran eli lilly Novartis Pelacarsen pharmaceutical sector Phase 3 Clinical Trials rap-cel +
Novartis’s Pelacarsen Fails to Reduce Cardiovascular Risk in Phase 3 Trial on September 08, 2026 Cardiovascular Diseases Cerebrovascular accident Clinical Trials Horizon Ionis Pharmaceuticals Lp(a ) Myocardial Infarction Novartis Pelacarsen Phase 3 +
Novartis stock drops after Avidity centerpiece fails Phase 3 trial on September 08, 2026 Avidity Biosciences clinical trial failure del-desiran drug pipeline HARBOR trial MYOTONIC DYSTROPHY 1 Novartis Pelacarsen Phase 3 +
Novartis drops after Avidity-acquired muscle-drug trial miss on September 08, 2026 Avidity Biosciences del-desiran DMPK gene HARBOR trial Lp(a)HORIZON MYOTONIC DYSTROPHY 1 Novartis Pelacarsen Phase III pipeline +
Lp(a): Why biotech is betting on the “diabolical” molecule on August 20, 2026 Antisense Oligonucleotides Biotech Market Cardiovascular Diseases Ionis Pharmaceuticals Lipoprotein(a ) Lp(a ) Novartis Pelacarsen RNA therapeutics +